All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Three months after agreeing to an intellectual property waiver for COVID-19 vaccines, World Trade Organization (WTO) members are discussing expanding it to therapies, diagnostics and devices used in preventing, diagnosing and treating COVID-19 infections.
Janssen Pharmaceutica NV has patented cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, rheumatoid arthritis and inflammatory disorders.
Xuanzhu Pharma Co. Ltd. has discovered new tricyclic compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has identified thiophene compounds acting as lysine-specific histone demethylase 1A (LSD1) inhibitors reported to be useful for the treatment of cancer.
Zhejiang University has disclosed transient receptor potential cation channel subfamily M member 2 (TRPM2) antagonists reported to be useful for the treatment of stroke and ischemia-reperfusion injury, among others.
Terns Pharmaceuticals Inc. has patented thyroid hormone receptor β (THRβ) agonists reported to be useful for the treatment of nonalcoholic steatohepatitis.
University of Michigan has described new proteolysis targeting chimeric (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to CREB-binding protein (CBP) and/or histone acetyltransferase KAT3B (p300)-targeting moiety through linker reported to be useful for the treatment of cancer.
Eli Lilly & Co. has synthesized macrocyclic peptides acting as amylin receptor agonists, glucose- and/or triglyceride-lowering agents reported to be useful for the treatment of type 2 diabetes, obesity, dyslipidemia and nonalcoholic steatohepatitis.
RSS
